METHODS FOR TREATING FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITINATED INCLUSIONS (FTLD-U)
    661.
    发明申请
    METHODS FOR TREATING FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITINATED INCLUSIONS (FTLD-U) 有权
    用非球面包扎法(FTLD-U)治疗球囊性变性的方法

    公开(公告)号:US20120178775A1

    公开(公告)日:2012-07-12

    申请号:US13343686

    申请日:2012-01-04

    Abstract: Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal; and c) causing an improvement of the learning, memory capacities and/or motor function of the animal.

    Abstract translation: 公开了拯救与泛素化包涵体(FTLD-U)的额颞叶退变相关的学习,记忆和/或运动功能缺陷的方法。 该方法包括:a)向具有FTLD-U的动物施用治疗有效量的自噬诱导物; b)导致动物脑中泛素化的TDP-43聚集形式的量减少; 和c)改善动物的学习,记忆能力和/或运动功能。

    MOLECULAR ION ACCELERATOR
    663.
    发明申请
    MOLECULAR ION ACCELERATOR 有权
    分子加速器

    公开(公告)号:US20120126112A1

    公开(公告)日:2012-05-24

    申请号:US13365105

    申请日:2012-02-02

    CPC classification number: H05H5/047 H01J49/06 H01J49/40 H01J49/403

    Abstract: A novel system and methods for accelerating analytes including, without limitation, molecular ions, biomolecules, polymers, nano- and microparticles, is provided. The invention can be useful for increasing detection sensitivity in applications such as mass spectrometry, performing collision-induced dissociation molecular structure analysis, and probing surfaces and samples using accelerated analyte.

    Abstract translation: 提供了一种用于加速分析物的新系统和方法,包括但不限于分子离子,生物分子,聚合物,纳米和微粒。 本发明可用于在诸如质谱法,进行碰撞诱导的解离分子结构分析和使用加速分析物的探测表面和样品等应用中提高检测灵敏度。

    Luminescent diamond particles
    664.
    发明授权
    Luminescent diamond particles 有权
    发光金刚石颗粒

    公开(公告)号:US08168413B2

    公开(公告)日:2012-05-01

    申请号:US11939311

    申请日:2007-11-13

    CPC classification number: C09K11/65 C01B32/28 Y10T428/2982

    Abstract: A method for preparing luminescent diamond particles (e.g., fluorescent nanodiamonds). The method includes irradiating diamond particles with an ion beam and heating the irradiated diamond particles in a non-oxidizing atmosphere at a temperature between 600 and 1000° C. The diamond particles have a diameter of 1 nm to 1 mm and the ion beam has a kinetic energy of 1 KeV to 900 MeV. Also disclosed are luminescent diamond particles prepared by this method and methods of using them.

    Abstract translation: 制备发光金刚石颗粒(例如荧光纳米金刚石)的方法。 该方法包括用离子束照射金刚石颗粒并在600-1000℃的温度下在非氧化性气氛中加热照射的金刚石颗粒。金刚石颗粒的直径为1nm至1mm,离子束具有 1 KeV至900 MeV的动能。 还公开了通过该方法制备的发光金刚石颗粒和使用它们的方法。

    Organic transistor inverter
    669.
    发明授权
    Organic transistor inverter 有权
    有机晶体管逆变器

    公开(公告)号:US08053769B2

    公开(公告)日:2011-11-08

    申请号:US12565109

    申请日:2009-09-23

    CPC classification number: H01L51/0504 H01L27/28

    Abstract: A transistor includes a first semiconductor layer associated with a first electrode; a second semiconductor layer associated with a second electrode; and a discontinuous layer between the first and second semiconductor layer. The discontinuous layer has a plurality of openings being formed on a non-uniform organic surface. Applications of the transistor include an inverter that operates at low supply voltage and high frequency.

    Abstract translation: 晶体管包括与第一电极相关联的第一半导体层; 与第二电极相关联的第二半导体层; 以及第一和第二半导体层之间的不连续层。 不连续层具有形成在非均匀有机表面上的多个开口。 晶体管的应用包括在低电源电压和高频率下工作的逆变器。

    Butanol extract of Bidens pilosa
    670.
    发明授权
    Butanol extract of Bidens pilosa 有权
    丁香的丁醇提取物

    公开(公告)号:US08048860B2

    公开(公告)日:2011-11-01

    申请号:US12263896

    申请日:2008-11-03

    CPC classification number: A61K36/28 C07H15/10

    Abstract: A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.

    Abstract translation: 治疗Th1介导的病症的方法包括向需要治疗的受试者施用有效量的式I化合物:其中R 1是H,烷基,芳基或环基; R2是吡喃糖; R3是H或烷基; m为2,3,4,5或6; n为0,1,2或3; o是0,1,2,3,4; p是1,2,3或4; 并且Th1介导的病症是非肥胖性糖尿病,克罗恩病的结肠炎,自身免疫性溶血性贫血,类风湿性关节炎,自身免疫性脑炎,多发性硬化或自身免疫性心肌炎。 还公开了包含上述式I化合物和药学上可接受的载体的药物组合物。

Patent Agency Ranking